Flecainide treats a novel KCNJ2 mutation associated with Andersen-Tawil syndrome

Hanora A Van Ert; Elise C McCune; Kate M Orland; Kathleen R Maginot; Nicholas H Von Bergen; Craig T January; Lee L Eckhardt

doi:10.1016/j.hrcr.2016.11.009

Flecainide treats a novel KCNJ2 mutation associated with Andersen-Tawil syndrome

HeartRhythm Case Rep. 2016 Dec 9;3(2):151-154. doi: 10.1016/j.hrcr.2016.11.009. eCollection 2017 Feb.

Authors

Hanora A Van Ert¹, Elise C McCune¹, Kate M Orland², Kathleen R Maginot², Nicholas H Von Bergen², Craig T January^{1

2}, Lee L Eckhardt^{1

2}

Affiliations

¹ Cellular and Molecular Arrhythmia Research Program, University of Wisconsin-Madison, Madison, Wisconsin.
² University of Wisconsin-Madison Inherited Arrhythmia Clinic, Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.

No abstract available

Keywords: Andersen-Tawil syndrome/long QT 7; Antiarrhythmic drugs; Genetic arrhythmia syndrome; KCNJ2 mutation; Ventricular arrhythmia–bidirectional ventricular tachycardia.

Publication types

Case Reports

Grants and funding

R01 HL128598/HL/NHLBI NIH HHS/United States